Position in PGEN
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$2,175,222
+$1,929,934 QoQ
Shares Held
381,618
+78.9% QoQ
Ownership
0.107%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#44
of 210 holders
Holding Since
Sep 2021
9 quarters on record
Voting authority
Sole 11%
Shared 0%
None 89%
Common Shares in PGEN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026LOS ANGELES CAPITAL MANAGEMENT LLC holds $888,466,927 across 167 Biotechnology names. PGEN ranks #21 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
729,635 | $219,642,024 | |
| 2 | HALO |
Halozyme Therapeutics, Inc.
|
1,938,035 | $151,689,999 | |
| 3 | CAI |
Caris Life Sciences, Inc.
|
3,958,531 | $70,541,022 | |
| 4 | INCY |
Incyte Corp
|
578,986 | $65,633,852 | |
| 5 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
130,802 | $64,973,277 | |
| 6 | EXEL |
Exelixis, Inc.
|
1,159,457 | $63,086,055 | |
| 7 | REGN |
Regeneron Pharmaceuticals, Inc.
|
98,585 | $61,471,690 | |
| 8 | RPRX |
Royalty Pharma plc
|
877,674 | $49,211,181 |
All Filings in PGEN
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2,175,222 | 381,618 | Shares | Sole | 2026-08-13 | |
| 2023-06-30 | $245,288 | 213,294 | Shares | Sole | 2023-08-03 | |
| 2023-03-31 | $458,700 | 432,736 | Shares | Sole | 2023-05-04 | |
| 2022-12-31 | $677,764 | 445,898 | Shares | Sole | 2023-02-06 | |
| 2022-09-30 | $1,054,042 | 497,190 | Shares | Sole | 2022-11-02 | |
| 2022-06-30 | $821,019 | 612,701 | Shares | Sole | 2022-08-05 | |
| 2022-03-31 | $1,326,981 | 628,901 | Shares | Sole | 2022-05-06 | |
| 2021-12-31 | $2,519,357 | 679,072 | Shares | Sole | 2022-02-03 | |
| 2021-09-30 | $2,595,234 | 520,087 | Shares | Sole | 2021-11-08 | |
| No filing history on record for this holder in this stock. | ||||||